Effectiveness and toxicity of hydroxyurea in children with sickle cell anemia;Eficácia e toxicidade da hidroxiuréia em crianças com anemia falciforme

Revista Brasileira de Hematologia e Hemoterapia

Volumn 28, Issue 2, 2006, Pages 144-148

  Silva, Michelle C ^a   Shimauti, Eliana L T ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Hydroxyurea; Pediatric population; Sickle cell anemia

Indexed keywords

EID: 33846387891     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842006000200016     Document Type: Review

References (54)

1. Embury, S.H. Anemia Falciforme e Hemoglobinopatias Associadas. In: Bennett, J.C. & Plum, F. Cecil Tratado de Medicina Interna. Rio de Janeiro: Guanabara Koogan, cap.137,p.976-988, 1997.
2. Naoum PC. Interferentes eritrocitários e ambientais na anemia falciforme. Rev Bras Hematol Hemoter 2000;22(1):5-22.
3. Silva RBP, et al. A anemia falciforme como problema de Saúde Pública no Brasil. Rev Saúde Pública 1993;27(1):54-58.
4. Manual de Diagnóstico e Tratamento de Doenças Falciformes. Brasília: Agência Nacional de Vigilância Sanitária - Anvisa, 2002.
5. Programa de Anemia Falciforme do Ministério da Saúde - Brasília, 1996.
6. Di Nuzzo DVP, Fonseca SF. Anemia falciforme e infecções. Jornal de Pediatria 2004;80(5):347-354.
7. Buchanan GR, et al. Sickle Cell Disease. American society of Hematology 2004; 35-47.
8. Ferster A, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97(11):3.628-3. 632.
9. Schnog JB, et al. Sickle cell disease; a general overview. The Journal of Medicine 2004;62(10):364-374.
10. Bandeira FMGC, et al. Hidroxiuréia em pacientes com síndromes falciformes acompanhados no Hospital Hemope, Recife, Brasil. Rev Bras Hematol Hemoter 2004;26(3):189-194.
11. Hanft VN, et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000;95(11):3.589-3.593.
12. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Seminars in Hematology 1997;34(3):42-47.
13. Scoot JP, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. Journal of Pediatrics 1996;128(6): 820-828.
14. Costa FF. Anemia falciforme. In: Zago MA, Falcão RP, Pasquini R. Hematologia: Fundamentos e Prática. São Paulo: Atheneu, cap.30, p.305, 2001.
15. Kratovil T, et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatric Blood & Cancer. Published online: 8 Mar, 2006.
16. Montalembert M, et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 2006;91(1):125-128.
17. Rotter M, et al. Molecular crowding limits the role of fetal hemoglobin in therapy for sickle cell disease. J Mol Biol 2005;347:1.015-1.023.
18. Venigalla P, et al. A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 2002;100(1): 363.
19. Meyappan JD, et al. Parents' assessment of risk in sickle cell treatment with hydroxyurea. J Pediatr Hematol Oncol 2005;27(12):644-650.
20. Galiza Neto GC, Pitombeira MS. Aspectos moleculares da anemia falciforme. Jornal Brasileiro de Patologia e Medicina Laboratorial 2003;39(1):51-56.
21. Brun M, et al. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression cultured human endothelial cells. Pharmacogenomics J 2003;3(4):215-226.
22. Covas DT, et al. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica 2004;89(3):273-280.
23. Gulbis B, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005;105(7):2.685-2.690.
24. Styles LA, et al. Decrease of very late activation Antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89(7):2.554-2.559.
25. Stuart A, et al. Insights into elevated distortion product otoacoustic emissions in sickle cell disease: Comparisons of hydroxyurea-treated and non-treated young children. Hearing Research 2006;212:83-89.
26. Lapoumeroulie C, et al. Decrease plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. Haematologica 2005;90(3):401-403.
27. Gupta K, et al. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endotelial cells by heparin. Biochim Biophys Acta1999;1453:63-73.
28. Lee SP, et al. Sickle cell adhesion to laminin: potencial role for the 5 chain. Blood 1998;92:2.951-2.958.
29. Wick TM, et al. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. J Clin Invest 1987;80:905-907.
30. Andrade SR, et al. Características hematológicas e bioquímicas da doença falciforme no estado do Rio Grande do Norte. Rev Bras Anál Clín 2001;33(4): 205-210.
31. Vicari P, et al. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia. American Journal of Hematology 2005;78(3): 243-244.
32. Zago MA. Defeitos hereditários das hemoglobinas. In: Zago MA, Falcão RP, Pasquini R. Hematologia Fundamentos e Prática. São Paulo: Atheneu, cap.29,p.279-287, 2001.
33. S-gene-cluster haplotypes in sickle cell anemia. In: Nagel RL (ed.). Hematology/Oncology Clinics of North America - Hemoglobinopathies 1991;5(3):475-93.
34. Galli A, Schiestl RH. Hydroxyurea induces recombination in diiding but not in G1 or G2 cell cycle arrested yeast cells. Mutat Res 1996; 354(1):69-75.
35. Lima PDL, et al. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Geneties and Molecular Research 2003;2(3):328-333.
36. a ed. São Paulo: Ganabara Koogan. cap.42, p.571, 2000.
37. Sakano K, et al. Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn J Cancer Res 2001; 92(11):1.166-1.174.
38. Ministério da Saúde, Portaria no 872 de 12 de Novembro de 2002. Art. 1° - Protocolo Clínico e Diretrizes Terapêuticas - Doença Falciforme - Hidroxiuréia. Secretário Renilson Rehem de Souza.
39. Kinney TR, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG - KIDS Study, a Phase I/II Trial. Blood 1999;94(5):1.550-1.554.
40. Ware RE, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004;145(3):346-352.
41. Hankins JS, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005;106(7): 2.269-2.275.
42. Ware RE, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004;145(3):346-352.
43. Zimmerman SA, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6): 2.039-2.045.
44. Ferster A, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97(11):3.628-3. 632.
45. Maier-Redelsperger M, et al. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. Blood 1998; 91(12):4.472-4.479.
46. Lavelle DE. The molecular mechanism of fetal hemoglobin reactivation. Semin Hematol 2004;41(4):3-10.
47. Hoppe C, et al. Use of hydroxyurea in children aged 2 to 5 years with sickle cell disease. J Pediatr Hemat Onco 2000;22:330-334.
48. Sumoza, A. et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 2002;71:161-165.
49. Montalembert M, Davis SC. Is hydroxyurea leukemogenic in children with sickle cell disease? Blood 2001;98(9):2.878-2.879.
50. Hu T, et al. Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotoxins. Mutat Res 2004; 549(1-2): 5-27.
51. Lee M, et al. Enhanced prediction of potential rodent carcinogenicity by utilizing comet assay and apoptotic assay in combination. Mutat Res 2003; 54(1-2):9-19.
52. Sarachek A, et al. Genetic destabilization of Candida albicans by hydroxyurea. Microbios 1991;65(262):39-61.
53. Severin I, et al. Toxic interaction between hydroxyurea and 1-beta-D-arabinofuranosylcytosine on the DNA of a human hepatoma cell line (HEPG2). Toxicol Lett 2003;145(3):3.003-311.
54. Torres AF, et al. Effect of hydroxyurea on hemoglobin S. Medicina 2003; 63(2): 140-142.